• J H Coombs, B J Bloom, F C Breedveld, M P Fletcher, D Gruben, J M Kremer, R Burgos-Vargas, B Wilkinson, C A F Zerbini, and S H Zwillich.
• Pfizer Inc, Ann Arbor, Michigan, USA.
• Ann. Rheum. Dis. 2010 Feb 1; 69 (2): 413-6.

ObjectivesTo determine the efficacy of CP-690,550 in improving pain, function and health status in patients with moderate to severe active rheumatoid arthritis (RA) and an inadequate response to methotrexate or a tumour necrosis factor alpha inhibitor.MethodsPatients were randomised equally to placebo, CP-690,550 5, 15 or 30 mg twice daily for 6 weeks, with 6 weeks' follow-up. The patient's assessment of arthritis pain (pain), patient's assessment of disease activity, Health Assessment Questionnaire-Disability Index (HAQ-DI) and Short Form-36 (SF-36) were recorded.ResultsAt week 6, significantly more patients in the CP-690,550 5, 15 and 30 mg twice-daily groups experienced a 50% improvement in pain compared with placebo (44%, 66%, 78% and 14%, respectively), clinically meaningful reductions in HAQ-DI (> or =0.3 units) (57%, 75%, 76% and 36%, respectively) and clinically meaningful improvements in SF-36 domains and physical and mental components.ConclusionsCP-690,550 was efficacious in improving the pain, function and health status of patients with RA, from week 1 to week 6.

33 keywords...

hide…